[{"Physician_Profile_ID": "806076", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "547.20", "Date_of_Payment": "09/13/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24490092", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "806076", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "464.40", "Date_of_Payment": "12/19/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24487569", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "806076", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "464.40", "Date_of_Payment": "11/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24487568", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "806076", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "309.60", "Date_of_Payment": "08/13/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24490091", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "806076", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "225.60", "Date_of_Payment": "08/13/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24490089", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "806076", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "225.60", "Date_of_Payment": "09/26/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24490090", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "806076", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "182.40", "Date_of_Payment": "09/26/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24490088", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "806076", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "154.80", "Date_of_Payment": "09/26/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24490087", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "806076", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "112.80", "Date_of_Payment": "09/26/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24490048", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma", "Research_Information_Link": "", "Context_of_Research": ""}]